Please login to the form below

Not currently logged in
Email:
Password:

S-A signs ophthalmology deal

Sanofi-aventis has signed a co-operation agreement with one of the main eye disease research centres in Europe

The ophthalmology division of sanofi-aventis (S-A), Fovea Pharmaceuticals, has signed a co-operation agreement with the Institut de la Vision (page is in French), one of the main eye disease research centres in Europe, for research in the diagnosis, prevention and treatment of ocular diseases.

The agreement aims to set up a partnership between S-A and the Institute on the model of translational R&D and to strengthen the company's collaboration with the organisations that make up the Institute, including the Pierre and Marie Curie University, the French National Institute of Health and Medical Research and the French National Center for Scientific Research.

Under the terms of the three-year agreement, S-A will be given priority access to the technological platforms of the Institute to conduct research activities and will support research and collaboration projects in particular in the area of regeneration of the optical nerve, vascular biology, inflammation and gene therapy in various eye tissues. S-A will be granted exclusive and worldwide rights to the results of the collaboration. In the case of commercialisation, it would pay royalties to members of the Institute.

Christopher A Viehbacher, CEO of S-A, said: "This collaboration will encourage the sharing of technical expertise and know-how with the objective to deliver innovative therapies for people with visual impairment and supports our ambition to build a global offer in ophthalmology for patients."

24th March 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics